On February 25, 2025 Santo Therapeutics reported recruitment of subjects for NF2 gene mutation-related solid tumors is now officially open.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
An open-label, single-arm, dose-escalation clinical study initiated by the Cancer Hospital of the Chinese Academy of Medical Sciences to evaluate the safety, tolerability, and preliminary efficacy of ST002 in patients with NF2 gene mutation-related solid tumors is now officially recruiting patients. The study drug is ST002 injection. Patients participating in this study will receive free access to the relevant examinations specified in the protocol, as well as the study drug .
The subjects recruited for this study should meet the following criteria:
1) Age ≥ 16 years old, gender not limited;
2) Benign or malignant solid tumors that meet the diagnostic criteria for NF2 gene mutation and have no standard treatment or have failed standard treatment;
3) There is at least one measurable and injectable superficial lesion, with the longest diameter of the tumor lesion baseline at the injection site >1.0 cm ;
4) It has sufficient organ and bone marrow function;
5) Patients must voluntarily participate in clinical trials, have good compliance, cooperate well with researchers, and sign a written informed consent form .
If you meet these key inclusion criteria and are willing to participate in this study, please contact us. After screening, a doctor will ultimately determine your eligibility and ability to participate in the study.
Recruitment period: From now on
Contact Person 1:Teacher Jiang 13261010586
Contact Person 2: Teacher Ma17349862185
(Press release, Santo Therapeutics, FEB 25, 2025, View Source;scene=1&srcid=03241eumHGHbS9qU0zullwfF&sharer_shareinfo=ee7432f17f07e091e676530751b67beb&sharer_shareinfo_first=ee7432f17f07e091e676530751b67beb#rd [SID1234663814])